Start-up aims to open the door to an entirely new approach to immunotherapy

Pathios Therapeutics raises $25M in first close of Series B financing to advance first-in-class immunotherapy approach into clinic

23-Apr-2024 - Pathios Therapeutics Limited, a biotech company focused on the development of first-in-class therapies for cancer, announced that the company has raised USD $25 million in the first close of a Series B financing. The financing consists of a new strategic investment from Bristol Myers Squibb, as ...